middle.news
Can Anteris Turn $65M Loss Into DurAVR Trial Success?
9:32am on Thursday 13th of November, 2025 AEDT
•
Healthcare
Read Story
Can Anteris Turn $65M Loss Into DurAVR Trial Success?
9:32am on Thursday 13th of November, 2025 AEDT
Key Points
Q3 2025 net loss of $22.2 million, $65.2 million for nine months
Initiation of PARADIGM pivotal trial after European and FDA approvals
Cash balance declined to $9.1 million at quarter-end
Completed $25.2 million private placement post-quarter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE